Two Cases of Treatment with Intrathecal Rituximab for Primary Central Nervous System Lymphoma.
10.3904/kjm.2014.87.2.224
- Author:
Yong Ho JANG
1
;
Tae Hwan HA
;
Deok Hee KIM
;
Sung Rok KIM
;
Young Jin YUH
;
Byeong Seok SOHN
;
Hye Ran LEE
Author Information
1. Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea. yjyuh@paik.ac.kr
- Publication Type:Case Report
- Keywords:
Primary CNS lymphoma;
Intrathecal immunotherapy;
Rituximab;
Lymphomatous meningitis
- MeSH:
B-Lymphocytes;
Central Nervous System*;
Cerebrospinal Fluid;
Drug Therapy;
Humans;
Immunotherapy;
Lymphoma*;
Lymphoma, Non-Hodgkin;
Meningitis;
Neuroimaging
- From:Korean Journal of Medicine
2014;87(2):224-228
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin's lymphoma (NHL), usually composed of diffuse large B-cells. Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab for PCNSL are limited. In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis. Both patients were refractory to conventional methotrexate-based intrathecal chemotherapy. However, after intrathecal rituximab with or without conventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinal fluid analysis. There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy.
